2 results
Approved WMORecruiting
To demonstrate the superiority of finerenone to placebo in reducing the rate of the composite CV endpoint.To determine superiority of finerenone to placebo for each secondary endpointTo assess the safety and tolerability of finerenone
Approved WMOPending
Primary Objective: To evaluate the *Triple Aim* performance of Care Pathway Technology for RA: - Evaluate and compare predefined RA health outcomes; Disease activity measured by DAS 28 joint score at baseline, month 12; RAPID3, HAQ-DI at baseline…